Format
Sort by

Send to

Choose Destination

Search results

Items: 1 to 20 of 131

1.

The effects of cannabis use on salience attribution: a systematic review.

Wijayendran SB, O'Neill A, Bhattacharyya S.

Acta Neuropsychiatr. 2016 Nov 21:1-15. [Epub ahead of print]

PMID:
27866486
2.

Traditional marijuana, high-potency cannabis and synthetic cannabinoids: increasing risk for psychosis.

Murray RM, Quigley H, Quattrone D, Englund A, Di Forti M.

World Psychiatry. 2016 Oct;15(3):195-204. doi: 10.1002/wps.20341.

3.

Sex and age specific effects of delta-9-tetrahydrocannabinol during the periadolescent period in the rat: The unique susceptibility of the prepubescent animal.

Silva L, Black R, Michaelides M, Hurd YL, Dow-Edwards D.

Neurotoxicol Teratol. 2016 Feb 16. pii: S0892-0362(16)30010-1. doi: 10.1016/j.ntt.2016.02.005. [Epub ahead of print] Review.

PMID:
26898326
4.

It's All in the Rhythm: The Role of Cannabinoids in Neural Oscillations and Psychosis.

Skosnik PD, Cortes-Briones JA, Hajós M.

Biol Psychiatry. 2016 Apr 1;79(7):568-77. doi: 10.1016/j.biopsych.2015.12.011. Review.

PMID:
26850792
5.

Marijuana Legalization: Impact on Physicians and Public Health.

Wilkinson ST, Yarnell S, Radhakrishnan R, Ball SA, D'Souza DC.

Annu Rev Med. 2016;67:453-66. doi: 10.1146/annurev-med-050214-013454. Review.

6.

Genetic moderation of the effects of cannabis: catechol-O-methyltransferase (COMT) affects the impact of Δ9-tetrahydrocannabinol (THC) on working memory performance but not on the occurrence of psychotic experiences.

Tunbridge EM, Dunn G, Murray RM, Evans N, Lister R, Stumpenhorst K, Harrison PJ, Morrison PD, Freeman D.

J Psychopharmacol. 2015 Nov;29(11):1146-51. doi: 10.1177/0269881115609073.

PMID:
26464454
7.

The effects of cannabis on memory function in users with and without a psychotic disorder: findings from a combined meta-analysis.

Schoeler T, Kambeitz J, Behlke I, Murray R, Bhattacharyya S.

Psychol Med. 2016 Jan;46(1):177-88. doi: 10.1017/S0033291715001646.

PMID:
26353818
8.

Cannabinoids and Schizophrenia: Risks and Therapeutic Potential.

Manseau MW, Goff DC.

Neurotherapeutics. 2015 Oct;12(4):816-24. doi: 10.1007/s13311-015-0382-6. Review.

9.

Synthetic cannabinoids: the dangers of spicing it up.

Salani DA, Zdanowicz MM.

J Psychosoc Nurs Ment Health Serv. 2015 May;53(5):36-43. doi: 10.3928/02793695-20150422-01. Review.

PMID:
25974923
10.

The relationship between cannabidiol and psychosis: A review.

Silva TB, Balbino CQ, Weiber AF.

Ann Clin Psychiatry. 2015 May;27(2):134-41. Review.

PMID:
25954940
11.

Risks associated with the non-medicinal use of cannabis.

Hoch E, Bonnetn U, Thomasius R, Ganzer F, Havemann-Reinecke U, Preuss UW.

Dtsch Arztebl Int. 2015 Apr 17;112(16):271-8. doi: 10.3238/arztebl.2015.0271. Review.

12.

The psychosis-like effects of Δ(9)-tetrahydrocannabinol are associated with increased cortical noise in healthy humans.

Cortes-Briones JA, Cahill JD, Skosnik PD, Mathalon DH, Williams A, Sewell RA, Roach BJ, Ford JM, Ranganathan M, D'Souza DC.

Biol Psychiatry. 2015 Dec 1;78(11):805-13. doi: 10.1016/j.biopsych.2015.03.023.

13.

Need for a comprehensive national survey of cannabis use.

Hamilton I.

BMJ. 2015 Mar 30;350:h1668. doi: 10.1136/bmj.h1668. No abstract available.

PMID:
25825416
14.

Impact of Cannabis Use on the Development of Psychotic Disorders.

Wilkinson ST, Radhakrishnan R, D'Souza DC.

Curr Addict Rep. 2014 Jun 1;1(2):115-128.

15.

High potency cannabis: a risk factor for dependence, poor psychosocial outcomes, and psychosis.

Hall W, Degenhardt L.

BMJ. 2015 Mar 4;350:h1205. doi: 10.1136/bmj.h1205. No abstract available.

PMID:
25739398
16.

Δ9-THC Disrupts Gamma (γ)-Band Neural Oscillations in Humans.

Cortes-Briones J, Skosnik PD, Mathalon D, Cahill J, Pittman B, Williams A, Sewell RA, Ranganathan M, Roach B, Ford J, D'Souza DC.

Neuropsychopharmacology. 2015 Aug;40(9):2124-34. doi: 10.1038/npp.2015.53.

17.

A systematic review of the antipsychotic properties of cannabidiol in humans.

Iseger TA, Bossong MG.

Schizophr Res. 2015 Mar;162(1-3):153-61. doi: 10.1016/j.schres.2015.01.033. Review.

PMID:
25667194
18.

The adverse health effects of synthetic cannabinoids with emphasis on psychosis-like effects.

van Amsterdam J, Brunt T, van den Brink W.

J Psychopharmacol. 2015 Mar;29(3):254-63. doi: 10.1177/0269881114565142. Review.

PMID:
25586398
19.

Impairment of inhibitory control processing related to acute psychotomimetic effects of cannabis.

Bhattacharyya S, Atakan Z, Martin-Santos R, Crippa JA, Kambeitz J, Malhi S, Giampietro V, Williams S, Brammer M, Rubia K, Collier DA, McGuire PK.

Eur Neuropsychopharmacol. 2015 Jan;25(1):26-37. doi: 10.1016/j.euroneuro.2014.11.018.

PMID:
25532865
20.

Use of synthetic cannabinoids in patients with psychotic disorders: case series.

Celofiga A, Koprivsek J, Klavz J.

J Dual Diagn. 2014;10(3):168-73. doi: 10.1080/15504263.2014.929364.

PMID:
25392292
Items per page

Supplemental Content

Loading ...
Support Center